FRIDAY, SEPTEMBER 30, 2016

DynPort Vaccine receives 10-year $90 million NIAID contract

DynPort Vaccine Company (DVC) LLC recently received a follow-on contract worth $90 million to continue to assist the National Institute of Allergy and Infectious Diseases (NIAID) with Phase 1 clinical trials for infectious disease therapeutics.

The  10-year Indefinite Delivery/Indefinite Quantity contract allows DVC and its partners to continue to finance and conduct studies to determine the safety of NIAID’s investigational therapeutic products, as well as to assess the pharmacodynamics and pharmacokinetic properties of the products to formulate proper dosages for patients.

Some of the investigational products are being developed to treat viral non-HIV infections, fungal and parasitic pathogens, and bacterial illnesses. Emerging and re-emerging infectious diseases also are being tested, as well as NIAID’s priority biodefense pathogens.

DVC will be the primary contractor in the studies. This requires the company to manage the clinical operations and general program’s concepts, protocol development and quality control.

Its partners, including Health Decisions, Quintiles and WCCT Global, will then enforce protocols and offer clinical research.

“DVC is pleased to continue supporting clinical trials to evaluate anti-infective drugs for NIAID,” Dr. Gary S. Nabors, president of DVC, said. “We have enjoyed a history of success under our existing NIAID contract; and together with our teaming partners, look forward to continuing our work with NIAID to evaluate new compounds for their potential to meet the growing need for new anti-infectives.”